{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:50:11Z","timestamp":1793065811703,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MZ SR","award":["2018\/37-LFUK-11"],"award-info":[{"award-number":["2018\/37-LFUK-11"]}]},{"DOI":"10.13039\/501100005357","name":"APVV","doi-asserted-by":"crossref","award":["APVV-15-0228"],"award-info":[{"award-number":["APVV-15-0228"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005357","name":"APVV","doi-asserted-by":"crossref","award":["APVV-21-0261"],"award-info":[{"award-number":["APVV-21-0261"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00982-4","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:37:30Z","timestamp":1781919450000},"page":"2139-2151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjunctive Dulaglutide in Relapsing\u2013Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-6363","authenticated-orcid":false,"given":"Pavel","family":"\u0160iarnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017dofia","family":"R\u00e1dikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislav","family":"Koll\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Kut\u0161\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Penesov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Havranov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Imrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Vl\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"\u017dit\u0148anov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Krastev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tur\u010d\u00e1ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"982_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-immunol-093019-124155","volume":"39","author":"V Ramaglia","year":"2021","unstructured":"Ramaglia V, Rojas O, Naouar I, Gommerman JL. The ins and outs of central nervous system inflammation-lessons learned from multiple sclerosis. Annu Rev Immunol. 2021;39:199\u2013226. https:\/\/doi.org\/10.1146\/annurev-immunol-093019-124155.","journal-title":"Annu Rev Immunol"},{"key":"982_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211007687","volume":"14","author":"S Haase","year":"2021","unstructured":"Haase S, Linker RA. Inflammation in multiple sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211007687. https:\/\/doi.org\/10.1177\/17562864211007687.","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"982_CR3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.18553\/jmcp.2023.23039","volume":"29","author":"M Schauf","year":"2023","unstructured":"Schauf M, Chinthapatla H, Dimri S, Li E, Hartung DM. Economic burden of multiple sclerosis in the United States: a systematic literature review. J Manag Care Spec Pharm. 2023;29(12):1354\u201368. https:\/\/doi.org\/10.18553\/jmcp.2023.23039.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"982_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-90 e2. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049.","journal-title":"Am J Med"},{"key":"982_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. https:\/\/doi.org\/10.1016\/j.molmet.2021.101351.","journal-title":"Mol Metab"},{"issue":"12","key":"982_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type\u00a02 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728\u201342. https:\/\/doi.org\/10.1038\/nrendo.2012.140.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"982_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67232","volume":"16","author":"AD Kaye","year":"2024","unstructured":"Kaye AD, Sala KR, Abbott BM, et al. The role of glucagon-like peptide-1 agonists in the treatment of multiple sclerosis: a narrative review. Cureus. 2024;16(8):e67232. https:\/\/doi.org\/10.7759\/cureus.67232.","journal-title":"Cureus"},{"issue":"1","key":"982_CR8","first-page":"17","volume":"41","author":"P Filippi","year":"2020","unstructured":"Filippi P, Vestenick\u00e1 V, Siarnik P, et al. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis. Neuro Endocrinol Lett. 2020;41(1):17\u201326.","journal-title":"Neuro Endocrinol Lett"},{"issue":"9","key":"982_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397.","journal-title":"N Engl J Med"},{"issue":"2","key":"982_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/13524585211017013","volume":"28","author":"A Kalinowski","year":"2022","unstructured":"Kalinowski A, Cutter G, Bozinov N, et al. The timed 25-foot walk in a large cohort of multiple sclerosis patients. Mult Scler. 2022;28(2):289\u201399. https:\/\/doi.org\/10.1177\/13524585211017013.","journal-title":"Mult Scler"},{"issue":"5","key":"982_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1352458517690824","volume":"23","author":"P Feys","year":"2017","unstructured":"Feys P, Lamers I, Francis G, et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017;23(5):711\u201320. https:\/\/doi.org\/10.1177\/1352458517690824.","journal-title":"Mult Scler"},{"issue":"5","key":"982_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721\u201333. https:\/\/doi.org\/10.1177\/1352458517690821.","journal-title":"Mult Scler"},{"issue":"4","key":"982_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10654-009-9327-x","volume":"24","author":"YT Lagerros","year":"2009","unstructured":"Lagerros YT, Bellocco R, Adami HO, Nyr\u00e9n O. Measures of physical activity and their correlates: the Swedish National March Cohort. Eur J Epidemiol. 2009;24(4):161\u20139. https:\/\/doi.org\/10.1007\/s10654-009-9327-x.","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"982_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/bf00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139. https:\/\/doi.org\/10.1007\/bf00280883.","journal-title":"Diabetologia"},{"issue":"2","key":"982_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0168-8227(90)90040-z","volume":"10","author":"J Cederholm","year":"1990","unstructured":"Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract. 1990;10(2):167\u201375. https:\/\/doi.org\/10.1016\/0168-8227(90)90040-z.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"982_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462\u201370. https:\/\/doi.org\/10.2337\/diacare.22.9.1462.","journal-title":"Diabetes Care"},{"issue":"1","key":"982_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11(1):812. https:\/\/doi.org\/10.1038\/s41467-020-14612-6.","journal-title":"Nat Commun"},{"issue":"6","key":"982_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857\u201370. https:\/\/doi.org\/10.1002\/ana.24954.","journal-title":"Ann Neurol"},{"issue":"6","key":"982_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3174\/ajnr.A1906","volume":"31","author":"KO L\u00f6vblad","year":"2010","unstructured":"L\u00f6vblad KO, Anzalone N, D\u00f6rfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol. 2010;31(6):983\u20139. https:\/\/doi.org\/10.3174\/ajnr.A1906.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"982_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/03007995.2011.639752","volume":"28","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin. 2012;28(1):49\u201356. https:\/\/doi.org\/10.1185\/03007995.2011.639752.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"982_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab229","volume":"3","author":"J Graf","year":"2021","unstructured":"Graf J, Leussink VI, Soncin G, et al. Relapse-independent multiple sclerosis progression under natalizumab. Brain Commun. 2021;3(4):fcab229. https:\/\/doi.org\/10.1093\/braincomms\/fcab229.","journal-title":"Brain Commun"},{"issue":"2","key":"982_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","volume":"28","author":"N De Stefano","year":"2014","unstructured":"De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28(2):147\u201356. https:\/\/doi.org\/10.1007\/s40263-014-0140-z.","journal-title":"CNS Drugs"},{"issue":"1","key":"982_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000109933","volume":"5","author":"B Engelhardt","year":"2008","unstructured":"Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis. 2008;5(1):16\u201322. https:\/\/doi.org\/10.1159\/000109933.","journal-title":"Neurodegener Dis"},{"key":"982_CR24","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.2147\/dmso.s375559","volume":"15","author":"M Dong","year":"2022","unstructured":"Dong M, Wen S, Zhou L. The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab Syndr Obes. 2022;15:2583\u201397. https:\/\/doi.org\/10.2147\/dmso.s375559.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"982_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2021;42(2):101\u201332. https:\/\/doi.org\/10.1210\/endrev\/bnaa032.","journal-title":"Endocr Rev"},{"issue":"11","key":"982_CR26","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/ijo.2015.136","volume":"39","author":"M Christensen","year":"2015","unstructured":"Christensen M, Sparre-Ulrich AH, Hartmann B, et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type\u00a02 diabetes. Int J Obes (Lond). 2015;39(11):1651\u20134. https:\/\/doi.org\/10.1038\/ijo.2015.136.","journal-title":"Int J Obes (Lond)"},{"key":"982_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, H\u00f6lscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33. https:\/\/doi.org\/10.1186\/1471-2202-13-33.","journal-title":"BMC Neurosci"},{"issue":"4","key":"982_CR28","doi-asserted-by":"publisher","first-page":"2292461","DOI":"10.1080\/21688370.2023.2292461","volume":"12","author":"EM Rhea","year":"2024","unstructured":"Rhea EM, Babin A, Thomas P, et al. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases. Tissue Barriers. 2024;12(4):2292461. https:\/\/doi.org\/10.1080\/21688370.2023.2292461.","journal-title":"Tissue Barriers"},{"issue":"3","key":"982_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cns.13791","volume":"28","author":"S Song","year":"2022","unstructured":"Song S, Guo R, Mehmood A, et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci Ther. 2022;28(3):422\u201334. https:\/\/doi.org\/10.1111\/cns.13791.","journal-title":"CNS Neurosci Ther"},{"key":"982_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek MA, Kandil EA, El Sayed NS, Sayed HM, Rabie MA. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int Immunopharmacol. 2023;115:109647. https:\/\/doi.org\/10.1016\/j.intimp.2022.109647.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"982_CR31","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10787-022-00956-6","volume":"30","author":"RA Ammar","year":"2022","unstructured":"Ammar RA, Mohamed AF, Kamal MM, Safar MM, Abdelkader NF. Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK\/SIRT1 signaling and NLRP3 inflammasome. Inflammopharmacology. 2022;30(3):919\u201334. https:\/\/doi.org\/10.1007\/s10787-022-00956-6.","journal-title":"Inflammopharmacology"},{"key":"982_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fphar.2016.00433","volume":"7","author":"B DellaValle","year":"2016","unstructured":"DellaValle B, Brix GS, Brock B, et al. Glucagon-like peptide-1 analog, liraglutide, delays onset of experimental autoimmune encephalitis in lewis rats. Front Pharmacol. 2016;7:433. https:\/\/doi.org\/10.3389\/fphar.2016.00433.","journal-title":"Front Pharmacol"},{"issue":"3","key":"982_CR33","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s13311-021-01088-5","volume":"18","author":"M Gharagozloo","year":"2021","unstructured":"Gharagozloo M, Smith MD, Sotirchos ES, et al. Therapeutic potential of a novel glucagon-like peptide-1 receptor agonist, NLY01 in experimental autoimmune encephalomyelitis. Neurotherapeutics. 2021;18(3):1834\u201348. https:\/\/doi.org\/10.1007\/s13311-021-01088-5.","journal-title":"Neurotherapeutics"},{"key":"982_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071584","author":"HC Chiou","year":"2019","unstructured":"Chiou HC, Lin MW, Hsiao PJ, et al. Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20071584.","journal-title":"Int J Mol Sci"},{"key":"982_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. https:\/\/doi.org\/10.1177\/20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"982_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.950623","volume":"10","author":"K Sango","year":"2022","unstructured":"Sango K, Takaku S, Tsukamoto M, Niimi N, Yako H. Glucagon-like peptide-1 receptor agonists as potential myelination-inducible and anti-demyelinating remedies. Front Cell Dev Biol. 2022;10:950623. https:\/\/doi.org\/10.3389\/fcell.2022.950623.","journal-title":"Front Cell Dev Biol"},{"issue":"30","key":"982_CR37","doi-asserted-by":"publisher","first-page":"6724","DOI":"10.1523\/jneurosci.5520-03.2004","volume":"24","author":"T Ogata","year":"2004","unstructured":"Ogata T, Iijima S, Hoshikawa S, et al. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci. 2004;24(30):6724\u201332. https:\/\/doi.org\/10.1523\/jneurosci.5520-03.2004.","journal-title":"J Neurosci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00982-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:33Z","timestamp":1784819493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00982-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00982-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors (Pavel \u0160iarnik, \u017dofia R\u00e1dikov\u00e1, Branislav Koll\u00e1r, Miroslava Kut\u0161\u00e1lov\u00e1, Adela Penesov\u00e1, Andrea Havranov\u00e1, Richard Imrich, Miroslav Vl\u010dek, Ingrid \u017dit\u0148anov\u00e1, Georgi Krastev, Peter Tur\u010d\u00e1ni) declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was registered in the EU Clinical Trials Register (EudraCT 2019-003001-94) and approved by the Ethics Committee of the Old Town Hospital, University Hospital Bratislava,\u00a0on 25 September 2019, under reference VV-2018-R-EK. The study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent after receiving detailed study information and training in the administration of dulaglutide.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}